NephroDI Therapeutics, Inc., a biopharmaceutical company developing NDI-5033 for the X-linked/congenital form of Nephrogenic Diabetes Insipidus (NDI), today announced a seed investment from Xontogeny, LLC to advance their lead program through critical preclinical work.

NephroDI Therapeutics is a pharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan indication. For more information, please visit: www.nephrodi.com.

https://nephrodi.com/

Philadelphia, Pennsylvania, United States

Nephrodi Therapeutics Lands Financing To Develop A Treatment For Nephrogenic Diabetes Insipidus, An Orphan Disease

Description

Company Information

Nephrodi Therapeutics Lands Financing To Develop A Treatment For Nephrogenic Diabetes Insipidus, An Orphan Disease

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information